Literature DB >> 1584567

Risk factors for retinal vein occlusions. A case-control study.

E Z Rath1, R N Frank, D H Shin, C Kim.   

Abstract

The authors conducted a case-control study of risk factors for retinal vein occlusions using 87 patients with vein occlusions, chosen randomly from photographic files from their institution between 1985 and 1990, and a control group of 85 subjects 38 years of age (the youngest individual in the vein occlusion group) or older, who were randomly selected from the records of two general ophthalmologists in the authors' department. Certain risk factors for retinal vein occlusion were highly significant when subjects with retinal vein occlusion were compared with the control group. These risk factors included systemic hypertension (odds ratio [OR], 3.86; 95% confidence interval [Cl], 2.08 to 7.16), open-angle glaucoma (OR, 2.89; 95% Cl, 1.38 to 6.05), and male sex (OR, 2.61; 95% Cl, 1.43 to 4.79). Race, presence of diabetes mellitus, history of coronary artery disease or stroke, and family history of diabetes, glaucoma, coronary artery disease, or stroke were not significant risk factors in the population studied. Logistic analysis of the risk factors showed no interactions. Risk factors for branch retinal vein occlusion and central retinal vein occlusion were identical.

Entities:  

Mesh:

Year:  1992        PMID: 1584567     DOI: 10.1016/s0161-6420(92)31940-2

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  41 in total

Review 1.  Thrombophilia: genetic polymorphisms and their association with retinal vascular occlusive disease.

Authors:  M Chak; G R Wallace; E M Graham; M R Stanford
Journal:  Br J Ophthalmol       Date:  2001-07       Impact factor: 4.638

2.  Baseline predictors of visual acuity and retinal thickness outcomes in patients with retinal vein occlusion: Standard Care Versus COrticosteroid for REtinal Vein Occlusion Study report 10.

Authors:  Ingrid U Scott; Paul C VanVeldhuisen; Neal L Oden; Michael S Ip; Barbara A Blodi; Mary Elizabeth Hartnett; Geoff Cohen
Journal:  Ophthalmology       Date:  2011-02       Impact factor: 12.079

3.  Superselective ophthalmic artery fibrinolytic therapy for the treatment of central retinal vein occlusion.

Authors:  M Paques; J N Vallée; D Herbreteau; A Aymart; P Y Santiago; F Campinchi-Tardy; D Payen; J J Merlan; A Gaudric; P Massin
Journal:  Br J Ophthalmol       Date:  2000-12       Impact factor: 4.638

4.  Thrombus and branch retinal vein occlusion.

Authors:  E Baglivo; A Dosso; C Pournaras
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-01       Impact factor: 3.117

Review 5.  Central retinal vein occlusion: what's the story?

Authors:  T H Williamson
Journal:  Br J Ophthalmol       Date:  1997-08       Impact factor: 4.638

6.  Measurement of lamina and prelaminar thicknesses of both eyes in patients with unilateral branch retinal vein occlusion.

Authors:  Yengwoo Son; Seungwoo Lee; Jongyeop Park
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-09-14       Impact factor: 3.117

Review 7.  [Retinal vein occlusions].

Authors:  S Dithmar; L L Hansen; F G Holz
Journal:  Ophthalmologe       Date:  2003-07       Impact factor: 1.059

8.  Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion.

Authors:  Thomas Ach; Alexandra E Hoeh; Karen B Schaal; Alexander F Scheuerle; Stefan Dithmar
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-09-09       Impact factor: 3.117

9.  Central retinal vein occlusion: a case report and review of the literature.

Authors:  Tarek Alasil; Nahyoung Lee; Pearse Keane; Srinivas Sadda
Journal:  Cases J       Date:  2009-06-03

10.  Venous retinal flow reperfusion mechanisms following radial optic neurotomy with adjunctive intraocular triamcinolone in central retinal vein occlusion.

Authors:  Pina Fortunato; Liliana Pollazzi; Maurizio Baroni; Attilio Evangelisti; Agostino La Torre
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-09-16       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.